Display options
Cite
Del Prete S, Caraglia M, Luce A, et al. Clinical and pathological factors predictive of response to neoadjuvant chemotherapy in breast cancer: A single center experience. Oncol Lett. 2019;18(4):3873-3879doi: 10.3892/ol.2019.10729.
Del Prete, S., Caraglia, M., Luce, A., Montella, L., Galizia, G., Sperlongano, P., Cennamo, G., Lieto, E., Capasso, E., Fiorentino, O., Aliberti, M., Auricchio, A., Iodice, P., & Addeo, R. (2019). Clinical and pathological factors predictive of response to neoadjuvant chemotherapy in breast cancer: A single center experience. Oncology letters, 18(4), 3873-3879. https://doi.org/10.3892/ol.2019.10729
Del Prete, Salvatore, et al. "Clinical and pathological factors predictive of response to neoadjuvant chemotherapy in breast cancer: A single center experience." Oncology letters vol. 18,4 (2019): 3873-3879. doi: https://doi.org/10.3892/ol.2019.10729
Del Prete S, Caraglia M, Luce A, Montella L, Galizia G, Sperlongano P, Cennamo G, Lieto E, Capasso E, Fiorentino O, Aliberti M, Auricchio A, Iodice P, Addeo R. Clinical and pathological factors predictive of response to neoadjuvant chemotherapy in breast cancer: A single center experience. Oncol Lett. 2019 Oct;18(4):3873-3879. doi: 10.3892/ol.2019.10729. Epub 2019 Aug 07. PMID: 31516598; PMCID: PMC6732960.
Copy Download .nbib Format: NLM
Share it on

Oncol Lett. 2019 Oct;18(4):3873-3879. doi: 10.3892/ol.2019.10729. Epub 2019 Aug 07.

Clinical and pathological factors predictive of response to neoadjuvant chemotherapy in breast cancer: A single center experience.

Oncology letters

Salvatore Del Prete, Michele Caraglia, Amalia Luce, Liliana Montella, Gennaro Galizia, Pasquale Sperlongano, Gregorio Cennamo, Eva Lieto, Elena Capasso, Olga Fiorentino, Maria Aliberti, Annamaria Auricchio, Patrizia Iodice, Raffaele Addeo

Affiliations

  1. Division of Medical Oncology, 'San Giovanni Di Dio Hospital', ASL NA2NORD, I-80027 Naples, Italy.
  2. Department of Precision Medicine, University of Campania 'L. Vanvitelli', I-80138 Naples, Italy.
  3. Division of Gastrointestinal Tract Surgical Oncology, Department of Translational Medical Sciences, University of Campania 'L. Vanvitelli', I-80138 Naples, Italy.
  4. Pathologist Department, Medicina Futura Group, I-80011 Naples, Italy.

PMID: 31516598 PMCID: PMC6732960 DOI: 10.3892/ol.2019.10729

Abstract

Neoadjuvant chemotherapy (NAC) of breast cancer (BC) improves outcomes, especially in patients with locally advanced and inflammatory cancer. Further insight into clinic-pathological factors influencing outcomes is essential to define the optimal therapeutic strategy for each category of patients and to predict the response to the treatment. In total, 117 patients with BC were treated with NAC with or without trastuzumab between 2010 and 2015. The histologic response to NAC was defined as a pathological complete response (pCR) when there was no evidence of residual invasive tumor in the breast or axillary lymph nodes. Relapse-free survival (RFS) was estimated using the Kaplan-Meier method and compared using log rank analysis. P-value <0.05 was considered statistically significant. The median age of the 117 patients enrolled in the present study was 52 years (age range, 35-85 years). The overall response rate (complete and partial responses) assessed by radiological and pathological evaluation were 76 and 72%, respectively. pCR was achieved in 35 out of 117 patients (~30%). In total, 6 patients (5%) developed progressive disease during chemotherapy. The RFS was 85 months (SE=3; 95% CI 79-91). The median was not reached and the mean follow-up time was 55 months (median 52 months; range 11-100 months). In this time, 20 patients (17%) experienced tumor recurrence. From the univariate analysis, the pathological response was significantly associated with receptor-based subtype, menopausal status and T-stage. From the multivariate analysis by using linear multiple regression and including receptor- menopausal status and T-stage, the model was not significant (P=0.062). However, by using the multiple logistic regression, and including age, pCR was significantly associated with ER+ HER2neg (P=0.006), T2 (P=0.043) and T3 (P=0.018). T-stage, menopausal status and receptor status are significantly associated with the pathological response in patients with inoperable BC treated with NAC.

Keywords: breast cancer; estrogen receptor; neoadjuvant chemotherapy; progesterone receptor; triple negative

References

  1. Lancet. 2003 Aug 2;362(9381):362-9 - PubMed
  2. Br J Cancer. 2005 Jan 17;92(1):147-55 - PubMed
  3. J Clin Oncol. 2006 Apr 20;24(12):1940-9 - PubMed
  4. Ann Surg Oncol. 2010 Sep;17(9):2411-8 - PubMed
  5. Ann Oncol. 2012 Sep;23 Suppl 10:x231-6 - PubMed
  6. Breast. 2014 Oct;23(5):526-37 - PubMed
  7. Breast Cancer Res Treat. 2015 Feb;150(1):127-39 - PubMed
  8. Breast. 2017 Apr;32:237-244 - PubMed
  9. J Breast Cancer. 2017 Jun;20(2):119-131 - PubMed
  10. J Surg Oncol. 2017 Dec;116(8):1021-1028 - PubMed
  11. Ann Oncol. 2017 Aug 1;28(8):1700-1712 - PubMed
  12. Breast Cancer Res Treat. 2018 Jan;167(1):277-288 - PubMed
  13. Breast Cancer Res Treat. 2018 Feb;168(1):285 - PubMed
  14. Expert Opin Biol Ther. 2018 Mar;18(3):251-262 - PubMed
  15. Lancet Oncol. 2018 Jan;19(1):27-39 - PubMed
  16. Ann Oncol. 2018 Mar 1;29(3):646-653 - PubMed
  17. World J Surg Oncol. 2018 Mar 7;16(1):51 - PubMed
  18. Medicine (Baltimore). 2018 May;97(20):e10634 - PubMed
  19. Front Oncol. 2018 May 22;8:156 - PubMed
  20. Cancers (Basel). 2018 Sep 20;10(10):null - PubMed
  21. JAMA. 2019 Jan 22;321(3):288-300 - PubMed

Publication Types